[
    {
        "pregunta": "1. What is the recommended treatment approach for DMARD-naive patients with moderate-to-high disease activity in rheumatoid arthritis, according to the 2021 American College of Rheumatology guideline?",
        "respuesta": "The recommended treatment approach for DMARD-naive patients with moderate-to-high disease activity in rheumatoid arthritis, according to the 2021 American College of Rheumatology guideline, is methotrexate monotherapy. Methotrexate is strongly recommended over hydroxychloroquine or sulfasalazine for these patients.",
        "contexto": [
            "therapy compared to clinicians. This preference was also stated in the 2015 guidelines When clinically relevant, recommendations specify the level of disease activity in the patient population (Table 1 7 In summary, this update includes recommendations related to initiation and adjustment of DMARD therapy in patients with RA. It also emphasizes the importance of minimizing use of glucocorticoids. It is expected that additional data may modify the direction and/or strength of specific recommendations. The ACR will update the recommendations and answer these and other questions as new data are published.    Supported by the American College of Rheumatology   OTR/I  OTR/L MEd",
            "csDMARDs and with a history of serious infection. However, the evidence was insufficient to support a recommendation. Future studies (using large registries and network meta-analyses) are needed to support specific recommendations for this patient population. The recommendation statements in this update are not directly comparable to the ACR 2015 guidelines  because they do not retain the early versus established RA subgroups. Nevertheless, there are some notable differences. First, the 2015 guidelines recommend csDMARD monotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients who are in remission. In this update, tapering recommendations are made for patients who are in low disease activity or remission in the face of a paucity of data about when",
            "| Disease activity levels refer to those calculated using RA disease activity measures endorsed by the ACR (10).                                   |\n| Recommendations are intended for the general RA patient population and assume that patients do not have contraindications to the options under consideration. |\n| Recommendations are limited to DMARDs approved by the US FDA for treatment of RA.                                                                |\n| csDMARDs: hydroxychloroquine, sulfasalazine, methotrexate, leflunomide.                                                                         |\n| bDMARDs: TNF inhibitors (etanercept, adalimumab, infliximab, golimumab, certolizumab pegol), T cell costimulatory inhibitor (abatacept), IL-6 receptor inhibitors (tocilizumab, sarilumab), anti-CD20 antibody (rituximab)â€  |\n| tsDMARDs: JAK inhibitors (tofacitinib, baricitinib, upadacitinib).                                                                               |",
            "<p>| <strong>Guiding Principles</strong>                                                                                                                       |\n|------------------------------------------------------------------------------------------------------------------------------------------------|\n| RA requires early evaluation, diagnosis, and management.                                                                                       |\n| Treatment decisions should follow a shared decision-making process.                                                                            |\n| Treatment decisions should be reevaluated within a minimum of 3 months based on efficacy and tolerability of the DMARD(s) chosen.               |\n| Disease activity levels refer to those calculated using RA disease activity measures endorsed by the ACR (10).                                   |",
            "review team, and panel members are listed in Supplementary Appendix 5, available on the Arthritis Care & Research website at http://online libr ary.wiley.com/doi/10.1002/acr.24596/ abstract Several guiding principles, definitions, and assumptions were established a priori (Table 1 RESULTS/RECOMMENDATIONS The recommendations are based on a set of 81 PICO questions. The literature review initially identified 22,971 manuscripts (for the full set of PICO questions covering both pharmacologic and nonpharmacologic treatment). After excluding 18,333 titles Recommendations for DMARD-naive patients with moderate-to-high disease activity (Table 2 DMARD monotherapy Methotrexate is strongly recommended over hydroxychloroquine or sulfasalazine for DMARDnaive patients with moderate-to-high disease activity This recommendation is strongly in favor of methotrexate despite very low-certainty evidence for hydroxychloroquine and low-certainty evidence for sulfasalazine based on the amount of data"
        ]
    },
    {
        "pregunta": "2. In patients with subcutaneous nodules and moderate-to-high disease activity, what is the preferred DMARD therapy based on the guideline?",
        "respuesta": "In patients with rheumatoid arthritis who have subcutaneous nodules and moderate-to-high disease activity, the 2021 American College of Rheumatology guideline conditionally recommends methotrexate over alternative DMARDs.",
        "contexto": [
            "therapy compared to clinicians. This preference was also stated in the 2015 guidelines When clinically relevant, recommendations specify the level of disease activity in the patient population (Table 1 7 In summary, this update includes recommendations related to initiation and adjustment of DMARD therapy in patients with RA. It also emphasizes the importance of minimizing use of glucocorticoids. It is expected that additional data may modify the direction and/or strength of specific recommendations. The ACR will update the recommendations and answer these and other questions as new data are published.    Supported by the American College of Rheumatology   OTR/I  OTR/L MEd",
            "csDMARDs and with a history of serious infection. However, the evidence was insufficient to support a recommendation. Future studies (using large registries and network meta-analyses) are needed to support specific recommendations for this patient population. The recommendation statements in this update are not directly comparable to the ACR 2015 guidelines  because they do not retain the early versus established RA subgroups. Nevertheless, there are some notable differences. First, the 2015 guidelines recommend csDMARD monotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients who are in remission. In this update, tapering recommendations are made for patients who are in low disease activity or remission in the face of a paucity of data about when",
            "as well as patient and clinician preferences. The voting panel cautioned that many patients treated with certain monoclonal antibodies may require ongoing treatment with methotrexate to prevent the formation of antidrug antibodies Recommendations for specific patient populations (Table 6) Subcutaneous nodules Methotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-tohigh disease activity Switching to a non-methotrexate DMARD is conditionally recommended over continuation of methotrexate for patients taking methotrexate with progressive subcutaneous nodules While accelerated nodulosis has been observed in patients starting methotrexate Pulmonary disease Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high",
            "<p>|Recommendations|Certainty of evidence|Evidence report(s) of the following PICO(s)|Supp. App. 2|\n|---|---|---|---|\n|Subcutaneous nodules| | | |\n|Methotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-to-high disease activity.|Very low|PICO 64|p. 427|\n|Switching to a non-methotrexate DMARD is conditionally recommended over continuation of methotrexate for patients taking methotrexate with progressive subcutaneous nodules.|Very low|PICO 65|p. 428|\n|Pulmonary disease| | | |\n|Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease who have moderate-to-high disease activity.|Very low|PICO 67|p. 430|\n|Heart failure| | | |",
            "| Disease activity levels refer to those calculated using RA disease activity measures endorsed by the ACR (10).                                   |\n| Recommendations are intended for the general RA patient population and assume that patients do not have contraindications to the options under consideration. |\n| Recommendations are limited to DMARDs approved by the US FDA for treatment of RA.                                                                |\n| csDMARDs: hydroxychloroquine, sulfasalazine, methotrexate, leflunomide.                                                                         |\n| bDMARDs: TNF inhibitors (etanercept, adalimumab, infliximab, golimumab, certolizumab pegol), T cell costimulatory inhibitor (abatacept), IL-6 receptor inhibitors (tocilizumab, sarilumab), anti-CD20 antibody (rituximab)â€  |\n| tsDMARDs: JAK inhibitors (tofacitinib, baricitinib, upadacitinib).                                                                               |"
        ]
    },
    {
        "pregunta": "3. For patients with pulmonary disease and moderate-to-high disease activity, what is the recommended DMARD treatment according to the guideline?",
        "respuesta": "The provided information does not include specific recommendations for the treatment of rheumatoid arthritis in patients with pulmonary disease and moderate-to-high disease activity according to the 2021 American College of Rheumatology guideline. Therefore, I cannot provide a reliable response based on the available data.",
        "contexto": [
            "csDMARDs and with a history of serious infection. However, the evidence was insufficient to support a recommendation. Future studies (using large registries and network meta-analyses) are needed to support specific recommendations for this patient population. The recommendation statements in this update are not directly comparable to the ACR 2015 guidelines  because they do not retain the early versus established RA subgroups. Nevertheless, there are some notable differences. First, the 2015 guidelines recommend csDMARD monotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients who are in remission. In this update, tapering recommendations are made for patients who are in low disease activity or remission in the face of a paucity of data about when",
            "| Disease activity levels refer to those calculated using RA disease activity measures endorsed by the ACR (10).                                   |\n| Recommendations are intended for the general RA patient population and assume that patients do not have contraindications to the options under consideration. |\n| Recommendations are limited to DMARDs approved by the US FDA for treatment of RA.                                                                |\n| csDMARDs: hydroxychloroquine, sulfasalazine, methotrexate, leflunomide.                                                                         |\n| bDMARDs: TNF inhibitors (etanercept, adalimumab, infliximab, golimumab, certolizumab pegol), T cell costimulatory inhibitor (abatacept), IL-6 receptor inhibitors (tocilizumab, sarilumab), anti-CD20 antibody (rituximab)â€  |\n| tsDMARDs: JAK inhibitors (tofacitinib, baricitinib, upadacitinib).                                                                               |",
            "therapy compared to clinicians. This preference was also stated in the 2015 guidelines When clinically relevant, recommendations specify the level of disease activity in the patient population (Table 1 7 In summary, this update includes recommendations related to initiation and adjustment of DMARD therapy in patients with RA. It also emphasizes the importance of minimizing use of glucocorticoids. It is expected that additional data may modify the direction and/or strength of specific recommendations. The ACR will update the recommendations and answer these and other questions as new data are published.    Supported by the American College of Rheumatology   OTR/I  OTR/L MEd",
            "review team, and panel members are listed in Supplementary Appendix 5, available on the Arthritis Care & Research website at http://online libr ary.wiley.com/doi/10.1002/acr.24596/ abstract Several guiding principles, definitions, and assumptions were established a priori (Table 1 RESULTS/RECOMMENDATIONS The recommendations are based on a set of 81 PICO questions. The literature review initially identified 22,971 manuscripts (for the full set of PICO questions covering both pharmacologic and nonpharmacologic treatment). After excluding 18,333 titles Recommendations for DMARD-naive patients with moderate-to-high disease activity (Table 2 DMARD monotherapy Methotrexate is strongly recommended over hydroxychloroquine or sulfasalazine for DMARDnaive patients with moderate-to-high disease activity This recommendation is strongly in favor of methotrexate despite very low-certainty evidence for hydroxychloroquine and low-certainty evidence for sulfasalazine based on the amount of data",
            "rheumatic diseases While consensus was easily reached on the majority of statements, 2 issues required prolonged discussion and debate. The decision on whether patients with an inadequate response to methotrexate should escalate to a bDMARD, tsDMARD, or triple therapy engendered much discussion with contrasting points of view. In the end, a recommendation was made in favor of a bDMARD or tsDMARD because of the more rapid onset of benefit and concerns related to the poor tolerability and durability of triple therapy in real-world practice Members of the voting panel agreed with the patient panel on the direction and strength of all but 2 recommendations. Patients were in favor of initial treatment with combination csD-MARDs over methotrexate monotherapy because they placed greater value on the incremental benefits associated with combination therapy compared to clinicians. This preference was also stated in the 2015 guidelines When clinically relevant, recommendations specify the level"
        ]
    },
    {
        "pregunta": "4. What is the suggested course of action for patients with heart failure and inadequate response to csDMARDs, as per the guideline?",
        "respuesta": "The 2021 American College of Rheumatology guideline conditionally recommends the addition of a nonâ€“TNF inhibitor biologic DMARD (bDMARD) or targeted synthetic DMARD (tsDMARD) over the addition of a TNF inhibitor for patients with NYHA class III or IV heart failure and an inadequate response to conventional synthetic DMARDs (csDMARDs).",
        "contexto": [
            "csDMARDs and with a history of serious infection. However, the evidence was insufficient to support a recommendation. Future studies (using large registries and network meta-analyses) are needed to support specific recommendations for this patient population. The recommendation statements in this update are not directly comparable to the ACR 2015 guidelines  because they do not retain the early versus established RA subgroups. Nevertheless, there are some notable differences. First, the 2015 guidelines recommend csDMARD monotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients who are in remission. In this update, tapering recommendations are made for patients who are in low disease activity or remission in the face of a paucity of data about when",
            "rheumatic diseases While consensus was easily reached on the majority of statements, 2 issues required prolonged discussion and debate. The decision on whether patients with an inadequate response to methotrexate should escalate to a bDMARD, tsDMARD, or triple therapy engendered much discussion with contrasting points of view. In the end, a recommendation was made in favor of a bDMARD or tsDMARD because of the more rapid onset of benefit and concerns related to the poor tolerability and durability of triple therapy in real-world practice Members of the voting panel agreed with the patient panel on the direction and strength of all but 2 recommendations. Patients were in favor of initial treatment with combination csD-MARDs over methotrexate monotherapy because they placed greater value on the incremental benefits associated with combination therapy compared to clinicians. This preference was also stated in the 2015 guidelines When clinically relevant, recommendations specify the level",
            "of, or discontinuation of, bDMARDs 86 DISCUSSION The recommendations presented herein are a companion to those published in 2019 The Voting Panel and Patient/Caregiver Panel both engaged in vigorous discussions over the use of NSAIDs and oral glucocorticoids Another major change in recommendations for the treatment of systemic JIA is the use of bDMARDs as initial treatment or upon inadequate response to a short course of NSAIDs. The addition of csDMARDs is recommended only for persistent synovitis despite treatment with bDMARDs. This recommendation reflects growing understanding about the roles of specific cytokines in systemic JIA and the ability to induce remission with targeted therapy against IL-6 and IL-1 The use of IAGCs was extensively discussed. Recommendations from 2011 and 2019 to preferentially use triamcinolone hexacetonide for oligoarthritis There is much that remains to be learned. Studies must be performed to obtain high-quality data to fill in the evidentiary gaps",
            "therapy compared to clinicians. This preference was also stated in the 2015 guidelines When clinically relevant, recommendations specify the level of disease activity in the patient population (Table 1 7 In summary, this update includes recommendations related to initiation and adjustment of DMARD therapy in patients with RA. It also emphasizes the importance of minimizing use of glucocorticoids. It is expected that additional data may modify the direction and/or strength of specific recommendations. The ACR will update the recommendations and answer these and other questions as new data are published.    Supported by the American College of Rheumatology   OTR/I  OTR/L MEd",
            "|Heart failure| | | |\n|Addition of a nonâ€“TNF inhibitor bDMARD or tsDMARD is conditionally recommended over addition of a TNF inhibitor for patients with NYHA class III or IV heart failure and an inadequate response to csDMARDs.|Very low|PICO 70|p. 435|\n|Switching to a nonâ€“TNF inhibitor bDMARD or tsDMARD is conditionally recommended over continuation of a TNF inhibitor for patients taking a TNF inhibitor who develop heart failure.|Very low|PICO 71|p. 436|\n|Lymphoproliferative disorder| | | |\n|Rituximab is conditionally recommended over other DMARDs for patients who have a previous lymphoproliferative disorder for which rituximab is an approved treatment and who have moderate-to-high disease activity.|Very low|PICO 75 and PICO 76|p. 446â€“7|\n|Hepatitis B infection| | | |"
        ]
    },
    {
        "pregunta": "5. In patients with lymphoproliferative disorder and moderate-to-high disease activity, what is the preferred DMARD therapy based on the guideline?",
        "respuesta": "The provided information does not include specific recommendations for the treatment of rheumatoid arthritis in patients with a lymphoproliferative disorder and moderate-to-high disease activity according to the 2021 American College of Rheumatology guideline. Therefore, I cannot provide a reliable response based on the available data.",
        "contexto": [
            "csDMARDs and with a history of serious infection. However, the evidence was insufficient to support a recommendation. Future studies (using large registries and network meta-analyses) are needed to support specific recommendations for this patient population. The recommendation statements in this update are not directly comparable to the ACR 2015 guidelines  because they do not retain the early versus established RA subgroups. Nevertheless, there are some notable differences. First, the 2015 guidelines recommend csDMARD monotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients who are in remission. In this update, tapering recommendations are made for patients who are in low disease activity or remission in the face of a paucity of data about when",
            "therapy compared to clinicians. This preference was also stated in the 2015 guidelines When clinically relevant, recommendations specify the level of disease activity in the patient population (Table 1 7 In summary, this update includes recommendations related to initiation and adjustment of DMARD therapy in patients with RA. It also emphasizes the importance of minimizing use of glucocorticoids. It is expected that additional data may modify the direction and/or strength of specific recommendations. The ACR will update the recommendations and answer these and other questions as new data are published.    Supported by the American College of Rheumatology   OTR/I  OTR/L MEd",
            "| Disease activity levels refer to those calculated using RA disease activity measures endorsed by the ACR (10).                                   |\n| Recommendations are intended for the general RA patient population and assume that patients do not have contraindications to the options under consideration. |\n| Recommendations are limited to DMARDs approved by the US FDA for treatment of RA.                                                                |\n| csDMARDs: hydroxychloroquine, sulfasalazine, methotrexate, leflunomide.                                                                         |\n| bDMARDs: TNF inhibitors (etanercept, adalimumab, infliximab, golimumab, certolizumab pegol), T cell costimulatory inhibitor (abatacept), IL-6 receptor inhibitors (tocilizumab, sarilumab), anti-CD20 antibody (rituximab)â€  |\n| tsDMARDs: JAK inhibitors (tofacitinib, baricitinib, upadacitinib).                                                                               |",
            "|Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors. There is no preferred agent.|Very low|PICO 27. In patients with systemic JIA in whom inactive disease is not achieved despite treatment with both IL-1 and IL-6 agents and/or who are chronically steroid dependent, is long-term stable steroid treatment superior to nonsteroid treatments (cyclophosphamide or abatacept or rituximab or IVIG or mesenchymal stem cell transplant or bone marrow transplant) for achievement of inactive disease, achievement of partial response, growth, ability to taper/discontinue steroids, and minimization of side effects/medication toxicity?|138|</p>",
            "|Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors.|Very low|PICO 27. In patients with systemic JIA in whom inactive disease is not achieved despite treatment with both IL-1 and IL-6 agents and/or who are chronically steroid dependent, is long-term stable steroid treatment superior to nonsteroid treatments (cyclophosphamide or abatacept or rituximab or IVIG or mesenchymal stem cell transplant or bone marrow transplant) for achievement of inactive disease, achievement of partial response, growth, ability to taper/discontinue steroids, and minimization of side effects/medication toxicity?|138|</p>"
        ]
    },
    {
        "pregunta": "6. How should healthcare providers manage patients with hepatitis B infection initiating rituximab therapy, as per the guideline?",
        "respuesta": "The 2021 American College of Rheumatology guideline strongly recommends prophylactic antiviral therapy over frequent monitoring alone for patients who are hepatitis B core antibody positive (regardless of hepatitis B surface antigen status) when initiating rituximab therapy.",
        "contexto": [
            "|Hepatitis B infection| | | |\n|Prophylactic antiviral therapy is strongly recommended over frequent monitoring alone for patients initiating rituximab who are hepatitis B core antibody positive (regardless of hepatitis B surface antigen status).|Very low|PICO 82|p. 459|\n|Prophylactic antiviral therapy is strongly recommended over frequent monitoring alone for patients initiating any bDMARD or tsDMARD who are hepatitis B core antibody positive and hepatitis B surface antigen positive.|Very low|PICO 83|p. 464|\n|Frequent monitoring alone is conditionally recommended over prophylactic antiviral therapy for patients initiating a bDMARD other than rituximab or a tsDMARD who are hepatitis B core antibody positive and hepatitis B surface antigen negative.|Very low|PICO 84|p. 471|\n|Nonalcoholic fatty liver disease| | | |",
            "III or IV heart failure without RA Lymphoproliferative disorder Rituximab is conditionally recommended over other DMARDs for patients who have a previous lymphoproliferative disorder for which rituximab is an approved treatment and who have moderate-to-high disease activity Rituximab is preferred over other DMARDs, regardless of previous DMARD experience, because it would not be expected to increase the risk of recurrence or worsening of these lymphoproliferative disorders. The recommendation is conditional because of the very low-certainty evidence supporting this PICO question. Hepatitis B infection Prophylactic antiviral therapy is strongly recommended over frequent monitoring of viral load and liver enzymes alone for patients initiating rituximab who are hepatitis B core antibody positive (regardless of hepatitis B surface antigen status) Prophylactic antiviral therapy is strongly recommended over frequent monitoring alone for patients initiating any bDMARD or tsDMARD who are",
            "status) Prophylactic antiviral therapy is strongly recommended over frequent monitoring alone for patients initiating any bDMARD or tsDMARD who are hepatitis B core antibody positive and hepatitis B surface antigen positive Frequent monitoring alone of viral load and liver enzymes is conditionally recommended over prophylactic antiviral therapy for patients initiating a bDMARD other than rituximab or a tsDMARD who are hepatitis B core antibody positive and hepatitis B surface antigen negative These recommendations were made based on the risk of hepatitis B reactivation due to core antibody and surface antigen status and the specific DMARD being initiated and are consistent with the updated American Association for the Study of Liver Diseases guidance Persistent hypogammaglobulinemia without infection In the setting of persistent hypogammaglobulinemia without infection, continuation of rituximab therapy for patients at target is conditionally recommended over switching to a different",
            "of patients, epidemiologists, and specialists in infectious diseases who represent other stakeholders for this project. This multidisciplinary collaboration facilitated the uptake and dissemination of the prior guideline, and it is anticipated that these recommendations will be similarly distributed and used to guide busy clinicians and their patients at the time of THA and TKA. GRADE methodology supports consensusbased recommendations that can be reached based on lowquality evidence across the critical outcomes and transparently rates the strength of the recommendation as well as the quality of the evidence supporting the recommendation Perioperative management of rituximab has been a challenge given the long dosing interval of 6 months and the recognized risk of severe infection linked to its use As previously, the recommendations that form this guideline are not treatment mandates. These recommendations will provide the backbone for a shared decision-making process between patient",
            "noted in the previous guideline, the patient's rheumatologist should be consulted regarding medication management. A patient with severe SLE who has been stable for >6 months or who has a history of recurrent or severe infections might discontinue the medications in the perioperative period. For patients with severe SLE undergoing THA or TKA, continuing belimumab and planning surgery in the last month of the dosing cycle of rituximab is conditionally recommended. In the prior guideline, rituximab was included in the recommendations with other biologics, but increased use for SLE treatment, the long dosing interval for rituximab, and the indication of belimumab as therapy for severe SLE manifestations has informed this change. Surgery should be planned at the end of the dosing cycle, typically during month 5 or 6 for patients receiving rituximab every 6 months, and to avoid disruptions of therapy rather than wait longer, given the long dosing interval for rituximab. The panel noted"
        ]
    },
    {
        "pregunta": "7. What is the recommended approach for DMARD-naive patients with nonalcoholic fatty liver disease and moderate-to-high disease activity, according to the guideline?",
        "respuesta": "The recommended treatment approach for DMARD-naive patients with nonalcoholic fatty liver disease, normal liver enzymes and liver function tests, and no evidence of advanced liver fibrosis who have moderate-to-high disease activity in rheumatoid arthritis, according to the 2021 American College of Rheumatology guideline, is methotrexate. Methotrexate is conditionally recommended over alternative DMARDs for these patients.",
        "contexto": [
            "|Nonalcoholic fatty liver disease| | | |\n|Methotrexate is conditionally recommended over alternative DMARDs for DMARD-naive patients with nonalcoholic fatty liver disease, normal liver enzymes and liver function tests, and no evidence of advanced liver fibrosis who have moderate-to-high disease activity.|Very low|PICO 87|p. 489|\n|Persistent hypogammaglobulinemia without infection| | | |\n|In the setting of persistent hypogammaglobulinemia without infection, continuation of rituximab therapy for patients at target is conditionally recommended over switching to a different bDMARD or tsDMARD.|Very low|PICO 66|p. 429|\n|Previous serious infection| | | |\n|Addition of csDMARDs is conditionally recommended over addition of a bDMARD or tsDMARD for patients with a serious infection within the previous 12 months who have moderate-to-high disease activity despite csDMARD monotherapy.|Very low|PICO 88|p. 490|",
            "therapy compared to clinicians. This preference was also stated in the 2015 guidelines When clinically relevant, recommendations specify the level of disease activity in the patient population (Table 1 7 In summary, this update includes recommendations related to initiation and adjustment of DMARD therapy in patients with RA. It also emphasizes the importance of minimizing use of glucocorticoids. It is expected that additional data may modify the direction and/or strength of specific recommendations. The ACR will update the recommendations and answer these and other questions as new data are published.    Supported by the American College of Rheumatology   OTR/I  OTR/L MEd",
            "| Disease activity levels refer to those calculated using RA disease activity measures endorsed by the ACR (10).                                   |\n| Recommendations are intended for the general RA patient population and assume that patients do not have contraindications to the options under consideration. |\n| Recommendations are limited to DMARDs approved by the US FDA for treatment of RA.                                                                |\n| csDMARDs: hydroxychloroquine, sulfasalazine, methotrexate, leflunomide.                                                                         |\n| bDMARDs: TNF inhibitors (etanercept, adalimumab, infliximab, golimumab, certolizumab pegol), T cell costimulatory inhibitor (abatacept), IL-6 receptor inhibitors (tocilizumab, sarilumab), anti-CD20 antibody (rituximab)â€  |\n| tsDMARDs: JAK inhibitors (tofacitinib, baricitinib, upadacitinib).                                                                               |",
            "csDMARDs and with a history of serious infection. However, the evidence was insufficient to support a recommendation. Future studies (using large registries and network meta-analyses) are needed to support specific recommendations for this patient population. The recommendation statements in this update are not directly comparable to the ACR 2015 guidelines  because they do not retain the early versus established RA subgroups. Nevertheless, there are some notable differences. First, the 2015 guidelines recommend csDMARD monotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients who are in remission. In this update, tapering recommendations are made for patients who are in low disease activity or remission in the face of a paucity of data about when",
            "review team, and panel members are listed in Supplementary Appendix 5, available on the Arthritis Care & Research website at http://online libr ary.wiley.com/doi/10.1002/acr.24596/ abstract Several guiding principles, definitions, and assumptions were established a priori (Table 1 RESULTS/RECOMMENDATIONS The recommendations are based on a set of 81 PICO questions. The literature review initially identified 22,971 manuscripts (for the full set of PICO questions covering both pharmacologic and nonpharmacologic treatment). After excluding 18,333 titles Recommendations for DMARD-naive patients with moderate-to-high disease activity (Table 2 DMARD monotherapy Methotrexate is strongly recommended over hydroxychloroquine or sulfasalazine for DMARDnaive patients with moderate-to-high disease activity This recommendation is strongly in favor of methotrexate despite very low-certainty evidence for hydroxychloroquine and low-certainty evidence for sulfasalazine based on the amount of data"
        ]
    },
    {
        "pregunta": "8. In patients with persistent hypogammaglobulinemia without infection, what is the guideline's recommendation regarding rituximab therapy continuation?",
        "respuesta": "The 2021 American College of Rheumatology guideline conditionally recommends the continuation of rituximab therapy in patients with hypogammaglobulinemia without infection, if the patients are at target, over switching to a different biologic DMARD (bDMARD) or targeted synthetic DMARD (tsDMARD). This recommendation is made because the clinical significance of hypogammaglobulinemia in patients without infection is uncertain. Additionally, it is not known if switching DMARDs in such patients is more effective in lowering infection risk while maintaining disease control than continuing rituximab.",
        "contexto": [
            "without infection, continuation of rituximab therapy for patients at target is conditionally recommended over switching to a different bDMARD or tsDMARD Continuing rituximab in patients who are at target is preferred because of the uncertain clinical significance of hypogammaglobulinemia in patients without infection. Although an increased risk of infection has been described in RA patients with hypogammaglobulinemia, it is not known if a switch in DMARDs in patients who are at target is more effective in lowering infection risk while maintaining disease control than continuation of rituximab. The recommendation is conditional because physician and patient risk tolerance is likely to vary depending on the degree of hypogammaglobulinemia and patient-specific risk factors for infection. Previous serious infection Addition of csDMARDs is conditionally recommended over addition of a bDMARD or tsDMARD for patients with a serious infection within the previous 12 months who have",
            "|Recommendation: For patients with GPA/MPA receiving remission maintenance therapy with rituximab who have hypogammaglobulinemia (e.g., IgG &lt;3 gm/liter) and recurrent severe infections, we conditionally recommend immunoglobulin supplementation.|44|Very low|\n|Ungraded position statement: The duration of non-GC remission maintenance therapy in GPA/MPA should be guided by the patientâ€™s clinical condition, preferences, and values.|26|Low to moderate|\n|Ungraded position statement: The duration of GC therapy for GPA/MPA should be guided by the patientâ€™s clinical condition, preferences, and values.|27, 33|Low to moderate|\n|Treatment of disease relapse| | |\n|Recommendation: For patients with GPA/MPA who have experienced relapse with severe disease manifestations and are not receiving rituximab for remission maintenance, we conditionally recommend treatment with rituximab over cyclophosphamide for remission re-induction.|28|Low|",
            "who have hypogammaglobulinemia (e.g., IgG <3 gm/liter) and recurrent severe infections, we conditionally recommend immunoglobulin supplementation. Immunoglobulin supplementation at replacement doses (e.g., 400-800 mg/kg/month) should be considered if a patient has hypogammaglobulinemia and is experiencing recurrent infections. Immunoglobulin supplementation can also be considered for patients with hypogammaglobulinemia without recurrent infections but with impaired vaccine responses Ungraded position statement: The duration of nonglucocor ticoid remission maintenance therapy in GPA/MPA should be guided by the patient's clinical condition, preferences, and values. The optimal duration of remission maintenance therapy is not well established. Although clinical trials have typically administered remission maintenance therapy for â‰¥18 months, patients may benefit from continuing remission maintenance therapy for a longer duration Ungraded position statement: The duration of glucocorticoid",
            "situation, preferences, and values should guide selection between them, given their comparable efficacy. Recommendation: For patients with GPA/MPA who are receiving rituximab for remission maintenance, we conditionally recommend scheduled re-dosing over using ANCA titers or CD19+ B cell counts to guide re-dosing. In one randomized trial, patients who received rituximab for remission maintenance based on changes in CD19+ B cell counts and/or ANCA titers had similar rates of relapse as those receiving rituximab as a scheduled dose. However, this study was limited by the small sample size, and there were wide CIs for the effect size Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally rec ommend treatment with methotrexate or azathioprine over mycophenolate mofetil for remission maintenance. Methotrexate and azathioprine are equally efficacious for remission maintenance Recommendation:",
            "rituximab every 6 months, and to avoid disruptions of therapy rather than wait longer, given the long dosing interval for rituximab. The panel noted that rituximab is used in SLE without an indication approved by the US Food and Drug Administration (FDA) but also noted that it has been included in SLE treatment guidelines This recommendation has changed since the prior guideline in part because of the additional indication for the use of belimumab in severe SLE including nephritis, as well as increased comfort with belimumab among clinicians and patients given its widespread use, low infection risk described in clinical trials, and inclusion in SLE treatment guidelines For patients with RA, AS, PsA, or all SLE for whom antirheumatic therapy was withheld prior to undergoing total joint arthroplasty, antirheumatic therapy should be restarted once the wound shows evidence of healing, any sutures/ staples are out, there is no significant swelling, erythema, or drainage, and there is no"
        ]
    },
    {
        "pregunta": "9. For patients with a history of serious infection within the previous 12 months and moderate-to-high disease activity, what is the recommended treatment approach according to the guideline?",
        "respuesta": "The provided information does not include specific recommendations for the treatment of patients with a history of serious infection within the previous 12 months and moderate-to-high disease activity according to the 2021 American College of Rheumatology guideline. Therefore, I cannot provide a reliable response based on the available data.",
        "contexto": [
            "csDMARDs and with a history of serious infection. However, the evidence was insufficient to support a recommendation. Future studies (using large registries and network meta-analyses) are needed to support specific recommendations for this patient population. The recommendation statements in this update are not directly comparable to the ACR 2015 guidelines  because they do not retain the early versus established RA subgroups. Nevertheless, there are some notable differences. First, the 2015 guidelines recommend csDMARD monotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients who are in remission. In this update, tapering recommendations are made for patients who are in low disease activity or remission in the face of a paucity of data about when",
            "decisions. METHODS Methodology overview. This guideline followed the American College of Rheumatology (ACR) guideline development process ( http://www.rheumatology.org/Practice-Quality/ Clinical-Support/Clinical-Practice-Guidelines http://onlinelibrary. wiley.com/doi/10.1002/art.40726/abstract http://onlinelibrary.wiley.com/doi/10.1002/art.40726/abstract In addressing pharmacologic therapies, we focused on immunomodulatory agents for long-term management rather than addressing acute symptom management (i.e., through intraarticular injections and the use of systemic glucocorticoids). Tofacitinib and ixekizumab were submitted for review and potential approval by the US Food and Drug Administration (FDA) at the time of formulation of this guideline There are currently no widely agreed-upon definitions of disease severity in PsA or psoriasis. Thus, health care providers and patients should judge PsA and psoriasis severity on a case-bycase basis. For the purpose of these recommendations,",
            "<h1>Table 6. Recommendations for treatment of patients with active psoriatic arthritis and comorbidities, including concomitant diabetes and recurrent serious infections (PICOs 63â€“66)*</h1>",
            "therapy compared to clinicians. This preference was also stated in the 2015 guidelines When clinically relevant, recommendations specify the level of disease activity in the patient population (Table 1 7 In summary, this update includes recommendations related to initiation and adjustment of DMARD therapy in patients with RA. It also emphasizes the importance of minimizing use of glucocorticoids. It is expected that additional data may modify the direction and/or strength of specific recommendations. The ACR will update the recommendations and answer these and other questions as new data are published.    Supported by the American College of Rheumatology   OTR/I  OTR/L MEd",
            "<h1>Table 4. Recommendations for treatment of patients with active psoriatic arthritis despite treatment with an IL-17i or an IL-12/23i biologic monotherapy (PICOs 36â€“43)*</h1>"
        ]
    },
    {
        "pregunta": "10. How should healthcare providers manage patients with nontuberculous mycobacterial lung disease and moderate-to-high disease activity despite csDMARD monotherapy, based on the guideline's recommendations?",
        "respuesta": "The 2021 American College of Rheumatology guidelines recommend the addition of abatacept over other biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) for patients with nontuberculous mycobacterial (NTM) lung disease and moderate-to-high disease activity who have not responded to csDMARD monotherapy. Additionally, it is conditionally recommended to use the lowest possible dose of glucocorticoids (discontinuation if possible) rather than continuing glucocorticoids without dose modification in these patients. These recommendations are made based on very low-certainty evidence.",
        "contexto": [
            "|Abatacept is conditionally recommended over other bDMARDs and tsDMARDs for patients with nontuberculous mycobacterial lung disease who have moderate-to-high disease activity despite csDMARDs.|Very low|PICO 93|p. 499|</p>",
            "tsDMARDs Abatacept is conditionally recommended over other bDMARDs and tsDMARDs for patients with NTM lung disease who have moderate-tohigh disease activity despite csDMARDs Abatacept is conditionally recommended over other bD MARDs and tsDMARDs based on population data extrapolated from studies on tuberculosis The preceding 3 recommendations are conditional because of the very low-certainty evidence supporting the analysis of the differences in treatment outcomes posed by these PICO questions. DISCUSSION The ACR guidelines were developed to provide clinicians with recommendations for decisions frequently faced in clinical practice. Several new topics are included in this update, including recommendations for administration of methotrexate, use of methotrexate in patients with subcutaneous nodules, pulmonary disease, and NAFLD, use of rituximab in patients with hypogammaglobulinemia, and treatment of RA in patients with NTM lung disease. Areas covered in the 2015 guidelines that are",
            "|Addition of/switching to DMARDs is conditionally recommended over initiation/dose escalation of glucocorticoids for patients with a serious infection within the previous 12 months who have moderate-to-high disease activity.|Very low|PICO 90 and PICO 91|p. 496â€“7|\n|Nontuberculous mycobacterial lung disease| | | |\n|Use of the lowest possible dose of glucocorticoids (discontinuation if possible) is conditionally recommended over continuation of glucocorticoids for patients with nontuberculous mycobacterial lung disease.|Very low|No relevant PICO| |\n|Addition of csDMARDs is conditionally recommended over addition of a bDMARD or tsDMARD for patients with nontuberculous mycobacterial lung disease who have moderate-to-high disease activity despite csDMARD monotherapy.|Very low|PICO 92|p. 498|",
            "is conditionally recommended over addition of a bDMARD or tsDMARD for patients with a serious infection within the previous 12 months who have moderate-to-high disease activity despite csDMARD monotherapy This conditional recommendation is made based on observational data suggesting a lower risk of infection associated with combination csDMARDs (dual or triple therapy) compared to bDMARDs or tsDMARDs Addition of/switching to DMARDs is conditionally recommended over initiation/dose escalation of glucocorticoids for patients with a serious infection within the previous 12 months who have moderate-to-high disease activity This conditional recommendation is made based on observational studies suggesting a strong association between dose and duration of glucocorticoids with the risk of serious infection Nontuberculous mycobacterial (NTM) lung disease Given the variability of NTM lung disease severity and response to treatment, patients should be closely comanaged with an infectious disease",
            "disease Given the variability of NTM lung disease severity and response to treatment, patients should be closely comanaged with an infectious disease or pulmonary specialist. Use of the lowest possible dose of glucocorticoids (discontinuation if possible) is conditionally recommended over continuation of glucocorticoids without dose modification for patients with NTM lung disease This recommendation is based on studies suggesting an increased risk of NTM lung disease in patients receiving either inhaled or oral glucocorticoids Addition of csDMARDs is conditionally recommended over addition of a bDMARD or tsDMARD for patients with NTM lung disease who have moderate-to-high disease activity despite csDMARD monotherapy This recommendation is based on the lower expected risk of NTM lung disease associated with csDMARDs compared to bDMARDs and tsDMARDs Abatacept is conditionally recommended over other bDMARDs and tsDMARDs for patients with NTM lung disease who have moderate-tohigh disease"
        ]
    }
]